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APPLYING BACKGROUND RISK DISTRIBUTION 
TO EVALUATE THE COST-EFFECTIVENESS OF 
THREE PREVENTIVE DRUG THERAPIES FOR 
OSTEOPOROTIC FRACTURES
Gao X1, Madhavan S2, Nau D2, Ambegaonkar A3, Islam S4, 
Rosenbluth S2, Amonkar M2
1PPD Development, Morrisville, NC, USA; 2West Virginia 
University School of Pharmacy, Morgantown, WV, USA; 3Pfizer 
Inc, New York, NY, USA; 4West Virginia University School of 
Medicine, Morgantown, WV, USA
OBJECTIVE: To evaluate cost-effectiveness (CE) of three
drug therapies for preventing osteoporotic fractures in post-
menopausal women from a state Medicaid Program per-
spective using the estimated risk distribution in the study
population. The three therapies are: hormone replacement
therapy (HRT), alendronate, and raloxifene. METHODS:
A hypothetical cohort of white women aged 45–85 years,
postmenopausal, and without past incidence of osteo-
porotic fractures was treated with one of the three alterna-
tives, and tracked over 3 years in a decision model. The CE
ratio was defined as the treatment costs [e.g., medications,
monitoring, adverse events (AE)] divided by the number
of fractures averted. Treatment Willingness-To-Continue
(WTC) rate was also considered. Data were collected from
literature, expert panel survey, Medicaid claims data, and a
risk survey in the study population. Monte Carlo simula-
tions were conducted (distributions used: background risk,
cost, and risk reduction rate). Risk or probability of os-
teoporotic fracture was also divided into three strata: low
(risk 0.1), medium (0.10.3). RESULTS: Compared to no
therapy, the expected CE of HRT was $29,119 per fracture
averted, alendronate: $35,101, and raloxifene: $39,760.
The incremental CE was $42,181 for alendronate (relative
to HRT) and $85,509 for raloxifene (relative to alen-
dronate). The incremental CE of alendronate and raloxifene
were $151,981 and $697,270 among women with low risk
(43% of the sample), compared to $11,099 and $34,017
respectively among high-risk women (26% of the sample).
CE was not sensitive to discount rate and AE probabilities.
CONCLUSIONS: HRT is the most cost-effective strategy
even though it may have relatively high monitoring and AE
costs, and low WTC rate. The significant decrease in mar-
ginal costs of Alendronate and Raloxifene in high-risk
women indicates an economic condition to use these two
drugs. The study provides a framework to make risk-appro-
priate coverage decisions for chemo-preventive agents.
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COST-MINIMIZATION ANALYSIS OF THE 
TREATMENT OF RHEUMATOID ARTHRITIS 
WITH LEFLUNOMIDE IN COMPARISON WITH 
THE COMBINATION OF INFLIXIMAB AND 
METHOTREXATE
Rubio-Terrés C1, Domínguez-Gil A2
1Aventis Pharma SA, Madrid, Spain; 2Hospital Universitario de 
Salamanca, Salamanca, Spain
OBJECTIVES: To carry out a pharmacoeconomic analy-
sis to compare the efficiency of two rheumatoid arthritis
treatments in Spain. METHODS: The study consisted of
a systematic review of efficacy and toxicity as well as a
cost-minimization analysis, carried out using a pharma-
coeconomic model, comparing the treatment with leflu-
nomide and the combination of infliximab and metho-
trexate during one year. RESULTS: Clinical trials directly
comparing both treatments are not available. The re-
sponse rate ACR20 combined, after one year, was 53.0%
(CI95%: 49.2%–56.4%) with Leflunomide and 42.0%
(CI95%: 31.2%–52.5%) with the combination of Inflix-
imab and Methotrexate (P  0.051). There were no sta-
tistically significant differences in the ACR50 response
(27.0 vs 21.0, respectively; P  0.19). There were fewer
infections with Leflunomide than with the combination,
both respiratory (15.0% and 34.0%, respectively; P 
0.0003) as well as urinary (0.0% and 3.0%, respectively;
P  0.10). In the basic case, the cost per patient of a
yearly treatment with Leflunomide or with Infliximab
and Methotrexate is estimated to be 315,023 Ptas (Span-
ish pesetas) (1,893 euros, €) and 2,596,286 Ptas (15,604 €),
respectively. Therefore, the incremental cost of the com-
bined treatment would be 2,281,263 Ptas (13,711 €). The
sensitivity analysis was carried out using the minimum
and maximum costs given by the standard deviations of
the unit costs and by modifiying other variables, as no
significant differences compared to the basic case were
found. CONCLUSIONS: The cost per patient after one
year of treatment is higher with the combination of In-
fliximab and Methotrexate compared to Leflunomide,
this is basically due to the higher acquisition cost of In-
fliximab.
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A COST-EFFECTIVENESS MODEL COMPARING 
CELECOXIB AND ROFECOXIB TO 
TRADITIONAL NSAIDS FOR
OSTEOARTHRITIS TREATMENT
Schaefer MG1,2, Morreale AP2, Plowman BK2
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OBJECTIVES: Recent studies have demonstrated slightly
improved gastrointestinal (GI) complication rates with
cyclooxygenase-2 (COX-2) inhibitors versus non-steroi-
dal anti-inflammatory (NSAID) medications in patients
not taking aspirin, however the cost avoidance from such
events alone does not justify the high costs of these
agents. Evidence that other non-GI adverse events may be
lower with COX-2 inhibitors is emerging. Since efficacy
of these agents appears to be similar, analysis of value
can be compared by evaluating adverse event profiles.
The purpose of this pharmacoeconomic model is to char-
acterize the relative cost-effectiveness of celecoxib and
rofecoxib compared to traditional NSAIDs in osteoar-
thritic patients not taking aspirin from the perspective of
the Veterans Affairs (VA) Health care System. METH-
Abstracts 71
ODS: Data from recently published outcome studies was
incorporated into TreeAge software to construct the one-
year decision analysis model. The primary cost drivers
thought to influence cost-effectiveness were complicated
GI bleeds, hospitalizations, and symptomatic ulcers, as
well as differences in renal toxicity, dyspepsia, anemia,
hypertension and edema. Sensitivity analysis was per-
formed on all major indices based on variations in results
found in reviewed studies. RESULTS: Overall rates of
adverse events were similar for all agents (75% NSAIDs,
72% celecoxib, 78% rofecoxib), however celecoxib was
associated with less events relating to primary cost driv-
ers. These differences are attributed mainly to variances
among adverse event probabilities for hypertension and
edema (NSAIDs 4.7%, 4.4%, celecoxib 1.6%, 2.9%, rofe-
coxib 6.4%, 6.3%, respectively). Cost of drug treatment
per year for NSAIDs, celecoxib, and rofecoxib are $36.00,
$466.00, and $482.00, respectively, based on Federal
Supply Schedule (FSS) pricing. CONCLUSIONS: Based
on preliminary data, therapy with COX-2 inhibitors does
not appear to be cost-effective to prescribe for all os-
teoarthritic patients within the VA Health care System.
Results may be extrapolated to other health care settings
assuming medical costs are similar.
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TREATMENT WITH LEFLUNOMIDE IMPROVES 
THE UTILITY OF PATIENTS WITH ACTIVE 
RHEUMATOID ARTHRITIS: AN APPLICATION 
OF THE SF-6D
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OBJECTIVES: To evaluate the changes in patient utility
with treatment of active rheumatoid arthritis (RA) with
leflunomide (LEF), placebo (PBO) or methotrexate
(MTX). METHODS: A 52 week multicenter double-
blind controlled trial comparing treatment with lefluno-
mide, methotrexate or placebo in patients with active
rheumatoid arthritis was used to derive patient utilities.
Short Form 36 (SF-36) data were used to generate utility
scores using the algorithm developed by Brazier et al
(1999). These utilities would reflect general population
values and would not be specific to an RA population.
Inclusion in the utility analysis required consistent SF-36
responses, a baseline and at least one other completed as-
sessment, and valid responses to derive the SF-6D utili-
ties. The area under the curve was calculated for com-
pleters and the intent-to-treat population in order to
estimate incremental quality adjusted life years (QALYs)
for the treatments. RESULTS: The clinical study popula-
tion consisted of 182 LEF, 180 MTX and 118 PBO pa-
tients. The population used for the utility analysis con-
sisted of 165 LEF, 164 MTX and 114 (PBO). Baseline
utility values were comparable between groups, ranging
from 0.622 to 0.637. Incremental QALYs gained for
completers was statistically significantly superior for LEF
over PBO (p  0.0317) and MTX (p  0.0130). Treat-
ment with LEF resulted in an incremental gain of 0.084
QALYs, starting from a baseline of 0.622. Similar results
were seen with the intent-to-treat population. CONCLU-
SIONS: Treatment of RA with LEF statistically improves
patient health state utility values and QALY gain over
MTX and PBO.
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EVALUATING DIRECT AND INDIRECT 
MEASURES OF UTILITY: STABILITY OF THE 
SF-6D IN A RHEUMATOID ARTHRITIS 
POPULATION
Crawford B1, Brazier JE2
1Mapi Values, Boston, MA, USA; 2University of Sheffield, 
Sheffield, UK
OBJECTIVES: To evaluate the stability and discrimina-
tive ability of direct and indirect measures of utility in a
population of rheumatoid arthritis patients. METHODS:
Clinical trial data was used to compare the stability of di-
rect measures of utility (SG and VAS) to that from an in-
direct approach to utility development (SF-6D). SF-36
data were transformed to the SF-6D utility using the al-
gorithm developed by Brazier et al.(1999) based on val-
ues of the general UK population. These data were com-
pared to SG and VAS data collected in the same trial.
Ability to discriminate across functional classes and vari-
ance around point estimates was examined. RESULTS:
The SF-6D generated utilities that were consistently
lower than the directly elicited SG and were closer to the
VAS valuations. The standard deviations, however, were
consistently smaller.
CONCLUSIONS: The indirect measure of utility (SF-6D)
was more stable in terms of variance of parameter esti-
mates and was able to discriminate across functional
classes. The reduced variance around these estimates en-
hances statistical testing and accurately reflects changes
experienced by the patient.
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COST IMPACT OF COX-2 INHIBITORS IN A 
MANAGED CARE PLAN: IMPLICATIONS FOR 
FORMULARY DECISION-MAKING
Atherly DE1, Fullerton DS2, Sturm LL2, Bryant A1, Sullivan SD1
1University of Washington, Seattle, WA, USA; 2Regence 
BlueShield, Seattle, WA, USA
BACKGROUND: Regence BlueShield, a 1.2 million-
member Washington health plan currently requires prior
Baseline Week 24 Week 52
SG 0.7759 (0.2399) 0.8684 (0.1850) 0.8794 (0.1858)
VAS 0.5902 (0.1942) 0.7425 (0.1623) 0.7701 (0.1629)
SF-6D 0.6287 (0.1290) 0.7323 (0.1109) 0.7443 (0.1089)
